Alzheimer's disease - Safety and dropout in long-term galantamine treatment in a routine clinical setting
276 patients with Alzheimer's disease receiving galantamine in the Swedish Alzheimer Treatment Study were investigated for safety and dropout. Completion rates and reasons for dropout were monitored. The occurrence and time of death was investigated. Galantamine was well tolerated and few side effects were observed. The most frequent cause of dropout during the first year was side effects (n=9), t